Amneal Pharmaceuticals earnings release, July 30, 2026

Amneal Pharmaceuticals, Inc. (AMRX) · Form 8-K, Item 2.02 · Filed · SEC filing

AMNEAL REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS – Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 – – Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 – – Raising 2026 Full Year Guidance – – Successful Debt Repricing in July Reduces Interest Cost – BRIDGEWATER, NJ, July 30, 2026 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX)

(“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026.

“Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.

Second Quarter 2026 Results

Net revenue in the second quarter of 2026 was $796 million, an increase of 10% compared to $725 million in the second quarter of 2025. Specialty net revenue increased 17%, driven by key branded products, including CREXONT®, BREKIYA® autoinjector, and UNITHROID®. Affordable Medicines net revenue increased

13%, driven by strong performance of our complex portfolio, including women’s health products, and new product launches. AvKARE net revenue decreased 4% due to a decline in the low margin distribution channel partially offset by growth in the government channel.

Net income attributable to Amneal Pharmaceuticals, Inc. was $58 million in the second quarter of 2026 compared to net income of $22 million in the second quarter of 2025, an increase of 157%, as higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SG&A expense.

Adjusted EBITDA in the second quarter of 2026 was $206 million, an increase of 12% compared to the second quarter of 2025, reflecting higher revenue and gross profit.

Diluted income per share in the second quarter of 2026 was $0.18 compared to diluted income per share of $0.07 for the second quarter of 2025, an increase of 157%, due to the aforementioned factors. Adjusted diluted earnings per share in the second quarter of 2026 was $0.30, an increase of 20% compared to $0.25 for the second quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.

Debt Repricing Further Reduces Future Interest Cost

In July 2026, the Company launched a repricing of its $2.084B Term Loan B, which will reduce the interest rate by 50 basis points from Secured Overnight Financing Rate (“SOFR”) plus 300 basis points to SOFR plus 250 basis points. The repricing is expected to close as early as August 3, 2026.

The Company also intends to obtain an additional $350 million Term Loan B financing to fund a portion of the purchase price of Kashiv Biosciences, as previously disclosed. Such additional Term Loans are expected to be incurred at the closing of the Kashiv acquisition at the reduced pricing. The repricing transaction is expected to generate about $12 million in annual cash interest savings and contribute towards the Company’s goal to reduce net leverage to below 3.0x by 2028.¹

Raising 2026 Full Year Guidance

We are raising select full year 2026 guidance metrics.

(1)

Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.

(2)

Accounts for 35% non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.

(3)

Represents cash provided by operating activities.

(4)

Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $30 million.

(5)

Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment.

Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Conference Call Information... (truncated)l. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Financial statements

Income Statement

We are raising select full year 2026 guidance metrics.

Updated GuidancePrior Guidance
Net revenue$3.10 billion - $3.20 billion$3.05 billion - $3.15 billion
Adjusted EBITDA (1)$750 million - $780 million$740 million - $770 million
Adjusted diluted EPS (2)$0.96 - $1.06$0.95 - $1.05
Operating cash flow (3)$350 million - $400 million$350 million - $400 million
Operating cash flow, excluding discrete items (4)$375 million - $425 million$375 million - $425 million
Capital expenditures (5)~$150 million~$110 million

Income Statement

Three Months Ended June 30, — (unaudited; in thousands, except per share amounts)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenue796,197724,5081,518,7161,419,928
Cost of goods sold461,689438,255864,095877,784
Gross profit334,508286,253654,621542,144
Selling, general and administrative148,722124,266287,582242,554
Research and development39,01747,96477,40088,004
Intellectual property legal development expenses2,0872,0173,6293,784
Acquisition costs7,60012,753
Restructuring and other charges5541,0241,2041,595
Charges (credit) related to legal matters, net8,057-3908,751-390
Other operating income-1,298-8,239-5,122
Operating income129,769111,372271,541211,719
Other (expense) income:Interest expense, net-55,043-65,101-108,404-122,040
Other (expense) income:Foreign exchange (loss) gain, net-1,9508,256-9,75012,503
Other (expense) income:Loss on refinancing-3,510
Other (expense) income:Increase in tax receivable agreement liability-2,439-4,420-106-15,107
Other (expense) income:Other income, net6531,6041,3952,122
Other (expense) income:Total other expense, net-58,779-59,661-120,375-122,522
Other (expense) income:Income before income taxes70,99051,711151,16689,197
Other (expense) income:Provision for income taxes1,37616,1013,55228,969
Other (expense) income:Net income69,61435,610147,61460,228
Other (expense) income:Less: Net income attributable to non-controlling interests-11,952-13,193-27,696-25,616
Other (expense) income:Net income attributable to Amneal Pharmaceuticals, Inc.57,66222,417119,91834,612
Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:Basic0.180.070.380.11
Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:Diluted0.180.070.370.11
Weighted-average common shares outstanding:Basic319,200313,739317,620312,404
Weighted-average common shares outstanding:Diluted328,102322,363328,527323,171

Income Statement

Three Months Ended June 30, — Reconciliation of Net Income to EBITDA and Adjusted EBITDA

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025Year Ended December 31, – 2025
Net income69,61435,610147,61460,228127,933
Adjusted to add:Interest expense, net55,04365,101108,404122,040241,091
Adjusted to add:Provision for income taxes1,37616,1013,55228,96911,276
Adjusted to add:Depreciation and amortization47,80060,11390,991120,272223,572
Adjusted to add:EBITDA (Non-GAAP)173,833176,925350,561331,509603,872
Adjusted to add (deduct):Stock-based compensation expense10,3928,27419,20815,40231,823
Adjusted to add (deduct):Acquisition, site closure, and idle facility expenses (1)8,0761,20313,7582,4445,301
Adjusted to add (deduct):Restructuring and other charges1,0244991,5954,208
Adjusted to add (deduct):Loss on refinancing (2)3,51031,365
Adjusted to add (deduct):Charges (credit) related to legal matters, net (3)8,057-3908,751-390-390
Adjusted to add (deduct):Asset impairment charges (4)3610423,022
Adjusted to add (deduct):Foreign exchange loss (gain)1,950-8,2569,750-12,503-7,635
Adjusted to add (deduct):Increase in tax receivable agreement liability2,4394,42010615,1076,588
Adjusted to add (deduct):Other (5)1,7034242,317370-9,739
Adjusted to add (deduct):Adjusted EBITDA (Non-GAAP)206,450183,660408,460353,638688,415

Income Statement

Three Months Ended June 30, — Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income69,61435,610147,61460,228
Adjusted to add (deduct):Non-cash interest6,9447,41113,6817,745
Adjusted to add (deduct):GAAP provision for income taxes1,37616,1013,55228,969
Adjusted to add (deduct):Amortization34,00444,82063,02589,094
Adjusted to add (deduct):Stock-based compensation expense10,3928,27419,20815,402
Adjusted to add (deduct):Acquisition, site closure, and idle facility expenses (1)8,0761,18913,7582,416
Adjusted to add (deduct):Restructuring and other charges1,0174991,588
Adjusted to add (deduct):Loss on refinancing3,510
Adjusted to add (deduct):Charges (credit) related to legal matters, including interest, net (3)9,117-39010,567-390
Adjusted to add (deduct):Asset impairment charges36104
Adjusted to add (deduct):Increase in tax receivable agreement liability2,4394,42010615,107

Income Statement

Three Months Ended June 30, 2026 — Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

Three Months Ended June 30, 2026 – As ReportedThree Months Ended June 30, 2026 – AdjustmentsThree Months Ended June 30, 2026 – Non-GAAPThree Months Ended June 30, 2025 – As ReportedThree Months Ended June 30, 2025 – AdjustmentsThree Months Ended June 30, 2025 – Non-GAAP
Net revenue796,197796,197724,508724,508
Cost of goods sold (1)461,689-33,317428,372438,255-44,050394,205
Gross profit334,50833,317367,825286,25344,050330,303
Gross margin %4246.239.545.6
Selling, general and administrative (2)148,722-13,781134,941124,266-11,424112,842
Research and development (3)39,017-85538,16247,964-1,57346,391
Intellectual property legal development expenses2,0872,0872,0172,017
Acquisition costs (4)7,600-7,600
Restructuring and other charges5545541,024-1,024
Charges (credits) related to legal matters, net (5)8,057-8,057-390390
Other operating income-1,298-1,298
Operating income129,76963,610193,379111,37257,681169,053

Income Statement

Six Months Ended June 30, 2026 — Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

Six Months Ended June 30, 2026 – As ReportedSix Months Ended June 30, 2026 – AdjustmentsSix Months Ended June 30, 2026 – Non-GAAPSix Months Ended June 30, 2025 – As ReportedSix Months Ended June 30, 2025 – AdjustmentsSix Months Ended June 30, 2025 – Non-GAAP
Net revenue1,518,7161,518,7161,419,9281,419,928
Cost of goods sold (1)864,095-61,628802,467877,784-87,565790,219
Gross profit654,62161,628716,249542,14487,565629,709
Gross margin %43.147.238.244.3
Selling, general and administrative (2)287,582-25,062262,520242,554-20,971221,583
Research and development (3)77,400-1,62875,77288,004-3,05384,951
Intellectual property legal development expenses3,6293,6293,7843,784
Acquisition costs (4)12,753-12,753
Restructuring and other charges1,204-4997051,595-1,595
Charges (credits) related to legal matters, net (5)8,751-8,751-390390
Other operating income-8,239-8,239-5,122-5,122
Operating income271,541110,321381,862211,719112,794324,513

Income Statement

Three Months Ended June 30, 2026 — (unaudited; $ in thousands)

Three Months Ended June 30, 2026 – As ReportedThree Months Ended June 30, 2026 – AdjustmentsThree Months Ended June 30, 2026 – Non-GAAPThree Months Ended June 30, 2025 – As ReportedThree Months Ended June 30, 2025 – AdjustmentsThree Months Ended June 30, 2025 – Non-GAAP
Net revenue489,913489,913433,425433,425
Cost of goods sold (2)282,684-14,513268,171252,646-11,171241,475
Gross profit207,22914,513221,742180,77911,171191,950
Gross margin %42.345.341.744.3
Selling, general and administrative (3)42,367-2,93939,42834,226-2,18332,043
Research and development (4)33,023-72532,29841,899-77741,122
Intellectual property legal development expenses2,0022,0021,9781,978
Restructuring and other charges683-683
Charges (credits) related to legal matters, net (5)8,057-8,057-390390
Other operating income-1,298-1,298
Operating income123,07826,234149,312102,38314,424116,807

Income Statement

Six Months Ended June 30, 2026 — (unaudited; $ in thousands)

Six Months Ended June 30, 2026 – As ReportedSix Months Ended June 30, 2026 – AdjustmentsSix Months Ended June 30, 2026 – Non-GAAPSix Months Ended June 30, 2025 – As ReportedSix Months Ended June 30, 2025 – AdjustmentsSix Months Ended June 30, 2025 – Non-GAAPSix Months Ended June 30, 2025 – Non-GAAP
Net revenue913,150913,150848,133848,133
Cost of goods sold (2)515,128-24,083491,045495,279-22,046473,233
Gross profit398,02224,083422,105352,85422,046374,900
Gross margin %43.646.241.644.2%
Selling, general and administrative (3)83,685-5,37178,31467,941-3,99963,942
Research and development (4)66,309-1,40264,90772,879-1,46671,413
Intellectual property legal development expenses3,4953,4953,6913,691
Restructuring and other charges683-683
Charges (credits) related to legal matters, net (5)8,751-8,751-390390
Other operating income-8,239-8,239-5,122-5,122
Operating income244,02139,607283,628213,17227,804240,976

Income Statement

Six Months Ended June 30, 2026 — (unaudited; $ in thousands)

Six Months Ended June 30, 2026 – As ReportedSix Months Ended June 30, 2026 – AdjustmentsSix Months Ended June 30, 2026 – Non-GAAPSix Months Ended June 30, 2025 – As ReportedSix Months Ended June 30, 2025 – AdjustmentsSix Months Ended June 30, 2025 – Non-GAAP
Net revenue282,560282,560236,340236,340
Cost of goods sold (1)91,285-37,54553,740108,878-65,52043,358
Gross profit191,27537,545228,820127,46265,520192,982
Gross margin %67.78153.981.7
Selling, general and administrative (2)74,786-1,19073,59661,292-83160,461
Research and development (3)11,091-22510,86615,125-1,58713,538
Intellectual property legal development expenses1341349393
Restructuring and other charges347-347471-471
Operating income104,91739,307144,22450,48168,409118,890

Income Statement

Three Months Ended June 30, 2026 — (unaudited; $ in thousands)

Three Months Ended June 30, 2026 – As ReportedThree Months Ended June 30, 2026 – AdjustmentsThree Months Ended June 30, 2026 – Non-GAAPThree Months Ended June 30, 2025 – As ReportedThree Months Ended June 30, 2025 – AdjustmentsThree Months Ended June 30, 2025 – Non-GAAP
Net revenue156,989156,989163,040163,040
Cost of goods sold130,740130,740129,814129,814
Gross profit26,24926,24933,22633,226
Gross margin %16.716.720.420.4
Selling, general and administrative (2)16,913-2,64814,26515,079-2,70012,379
Operating income9,3362,64811,98418,1472,70020,847

Income Statement

Six Months Ended June 30, 2026 — (unaudited; $ in thousands)

Six Months Ended June 30, 2026 – As ReportedSix Months Ended June 30, 2026 – AdjustmentsSix Months Ended June 30, 2026 – Non-GAAPSix Months Ended June 30, 2025 – As ReportedSix Months Ended June 30, 2025 – AdjustmentsSix Months Ended June 30, 2025 – Non-GAAP
Net revenue323,006323,006335,455335,455
Cost of goods sold257,682257,682273,627273,627
Gross profit65,32465,32461,82861,828
Gross margin %20.220.218.418.4
Selling, general and administrative (2)33,593-5,29628,29730,773-5,40025,373
Operating income31,7315,29637,02731,0555,40036,455

Balance Sheet

June 30, 2026 — (unaudited; in thousands)

June 30, 2026December 31, 2025
Current assets:Cash and cash equivalents127,637282,029
Current assets:Restricted cash8,64328,842
Current assets:Trade accounts receivable, net1,020,360895,143
Current assets:Inventories677,954606,302
Current assets:Prepaid expenses and other current assets112,01198,395
Current assets:Related party receivables424470
Current assets:Total current assets1,947,0291,911,181
Current assets:Property, plant and equipment, net456,877442,950
Current assets:Goodwill593,499595,470
Current assets:Intangible assets, net587,830563,498
Current assets:Operating lease right-of-use assets44,36138,832
Current assets:Operating lease right-of-use assets - related party13,72315,216
Current assets:Financing lease right-of-use assets52,36053,328
Current assets:Other assets80,66957,805
Current assets:Total assets3,776,3483,678,280
Current liabilities:Accounts payable and accrued expenses721,208761,316
Current liabilities:Current portion of liabilities for legal matters18,48843,256
Current liabilities:Revolving credit facility100,000
Current liabilities:Current portion of long-term debt, net5,9616,761
Current liabilities:Current portion of operating lease liabilities9,0408,668
Current liabilities:Current portion of operating lease liabilities - related party2,8992,705
Current liabilities:Current portion of financing lease liabilities3,5213,442
Current liabilities:Related party payables - short term22,07055,485
Current liabilities:Total current liabilities883,187881,633
Current liabilities:Long-term debt, net2,564,3352,565,115
Current liabilities:Operating lease liabilities38,69133,233
Current liabilities:Operating lease liabilities - related party12,71214,195
Current liabilities:Financing lease liabilities54,60254,927
Current liabilities:Related party payables - long term2,89219,132
Current liabilities:Liabilities for legal matters - long term70,83071,819
Current liabilities:Other long-term liabilities32,11932,263
Current liabilities:Total long-term liabilities2,776,1812,790,684
Current liabilities:Redeemable non-controlling interests83,95677,292
Current liabilities:Total stockholders’ equity (deficiency)33,024-71,329
Current liabilities:Total liabilities and stockholders’ equity (deficiency)3,776,3483,678,280
Full release

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our positioning and potential growth, statements regarding our ability to create long-term value, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other² events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to our proposed transaction to acquire membership interests of Kashiv BioSciences, LLC (“Kashiv”), our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working³ capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

Contact

Anthony DiMeo

VP, Investor Relations anthony.dimeo@amneal.com⁴

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Operations

(unaudited; in thousands, except per share amounts)⁵

Amneal Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(unaudited; in thousands)⁶

Amneal Pharmaceuticals, Inc.

Consolidated Statements of Cash Flows

(unaudited; in thousands)⁷

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, in thousands)

Reconciliation of Net Income to EBITDA and Adjusted EBITDA⁸

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Calculation of Net Debt and Net Leverage⁹

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited; in thousands, except per share amounts)

Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share¹⁰

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited)

Explanations for Non-GAAP Reconciliations

(1)

Acquisition, site closure, and idle facility expenses for the three and six months ended June 30, 2026 primarily included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three and six months ended June 30, 2025 and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties.

(2)

For the year ended December 31, 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to

Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2025.

(3)

For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million,... (truncated)on. For the three and six months ended June 30, 2026, charges related to legal matters, including interest, net also included interest expense associated with the Nationwide Opioids Settlement Agreement. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to

Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

(4)

For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application.

(5)

For the year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain.

(6)

Refer to

Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information.

(7)

Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.

(8)

Gross leverage was calculated by dividing gross debt as of June 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended June 30, 2026 and year ended December 31, 2025, respectively.

(9)

Net leverage was calculated by dividing net debt as of June 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended June 30, 2026 and year ended December 31, 2025, respectively.

(10)

The non-GAAP effective tax rates for the three and six months ended June 30, 2026 were 25.1% and 24.7%, respectively. The non-GAAP effective tax rates for the three and six months ended June 30, 2025 were 24.7% and 25.0%, respectively.

(11)

Weighted average diluted shares outstanding for the three and six months ended June 30, 2026 and 2025 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities).¹¹

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

(1)

Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million in each period) and amortization expense ($32.3 million and $43.1 million).

(2)

Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($8.6 million and $6.4 million), amortization expense ($2.6 million and $2.7 million), site closure costs ($0.5 million in each period), and other ($2.1 million and $1.8 million).

(3)

Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.9 million in each period) and site closure costs (none and $0.7 million).

(4)

Acquisition costs for the three months ended June 30, 2026 included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.

(5)

For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For additional information regarding antitrust class action litigation, refer to

Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.¹²

Amneal Pharmaceuticals, Inc.

Non-GAAP Reconciliations

(unaudited, $ in thousands)

Reconciliation of Consolidated GAAP to Non-GAAP Operating Results

(1)

Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.0 million and $1.9 million), amortization expense ($59.6 million and $85.6 million), and asset impairment charges (none and $0.1 million).

(2)

Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($15.6 million and $11.9 million), amortization expense ($5.3 million and $5.4 million), site closure costs ($1.0 million in each period), and other ($3.2 million and $2.6 million).

(3)

Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.6 million and $1.7 million) and site closure costs (none and $1.4 million).

(4)

Acquisition costs for the six months ended June 30, 2026 included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.

(5)

For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to

Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.¹³

Amneal Pharmaceuticals, Inc.

Affordable Medicines Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(1)

(unaudited; $ in thousands)

(1)

Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)

Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million and $0.9 million) and amortization expense ($13.5 million and $10.3 million).

(3)... (truncated)ensation expense ($2.5 million and $1.6 million) and site closure costs ($0.5 million and $0.6 million).

(4)

Adjustments for the three months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(5)

For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For additional information regarding antitrust class action litigation, refer to

Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.¹⁴

Amneal Pharmaceuticals, Inc.

Affordable Medicines Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(1)

(unaudited; $ in thousands)

(1)

Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)

Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.0 million and $1.8 million), amortization expense ($22.1 million and $20.1 million), and asset impairment charges (none and $0.1 million).

(3)

Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($4.4 million and $2.9 million) and site closure costs ($1.0 million and $1.1 million).

(4)

Adjustments for the six months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(5)

For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to

Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.¹⁵

Amneal Pharmaceuticals, Inc.

Specialty Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(unaudited; $ in thousands)

(1)

Adjustments for the three months ended June 30, 2026 and 2025 were comprised of amortization expense.

(2)

Adjustments for the three months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(3)

Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.1 million in each period) and site closure costs (none and $0.7 million).¹⁶

Amneal Pharmaceuticals, Inc.

Specialty Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(unaudited; $ in thousands)

(1)

Adjustments for the six months ended June 30, 2026 and 2025 were comprised of amortization expense.

(2)

Adjustments for the six months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.

(3)

Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.2 million in each period) and site closure costs (none and $1.4 million).¹⁷

Amneal Pharmaceuticals, Inc.

AvKARE Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(1)

(unaudited; $ in thousands)

(1)

Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)

Adjustments for the three months ended June 30, 2026 and 2025 were comprised of amortization expense.¹⁸

Amneal Pharmaceuticals, Inc.

AvKARE Segment

Reconciliation of GAAP to Non-GAAP Operating Results

(1)

(unaudited; $ in thousands)

(1)

Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.

(2)

Adjustments for the six months ended June 30, 2026 and 2025 were comprised of amortization expense.¹⁹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Amneal Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.